MCK outlook supported by Q1 growth and $2.25B Precision acquisition
MCK said strategic focus on oncology and supply chain, including its $2.25B Precision Medicine Group acquisition, supports a positive outlook alongside robust Q1 growth, AI and technology investments, and biosimilar opportunities.
Strategic focus remains on oncology, biopharma, and supply chain, highlighted by the $2.25B Precision Medicine Group acquisition, robust Q1 growth in key segments, and disciplined capital allocation. AI and technology investments, stable generics, and biosimilar opportunities support a positive out…